camptothecin has been researched along with tamoxifen in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Akula, B; Bharathi, EV; Billa, VK; Cosenza, SC; Gallo, JM; Lv, H; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Barrett, JC; Dunn, SE; Hardman, RA; Kari, FW | 1 |
| Enomoto, K | 1 |
| Chen, TC; Fry, D; Liebes, L; Su, S | 1 |
| Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL | 1 |
| Lee, SY; McLeod, HL | 1 |
| Sai, K; Saito, Y | 1 |
| Begg, EJ; Helsby, NA; Jensen, BP | 1 |
| Coward, L; Darby, A; Gorman, GS; Rasberry, B | 1 |
| Coward, L; Gorman, G; Grappe, F; Nance, G | 1 |
| Bilensoy, E | 1 |
| Ise, Y; Kitagawa, C; Saka, H | 1 |
| Li, FY; Liu, L; Liu, ZQ; Lu, L; Peng, XJ; Qi, XX; Shi, J; Wang, Y; Zhou, FY; Zhou, J | 1 |
| Guo, GL; Schumacher, JD | 1 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
7 review(s) available for camptothecin and tamoxifen
| Article | Year |
|---|---|
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Pharmacogenomics of tamoxifen and irinotecan therapies.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome | 2008 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Ethnicity; Gemcitabine; Genetic Markers; Genotype; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Single Nucleotide; Tamoxifen | 2011 |
Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.
Topics: Aryl Hydrocarbon Hydroxylases; Azathioprine; Camptothecin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Enzymes; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Methyltransferases; Mixed Function Oxygenases; Prodrugs; Tamoxifen; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2012 |
Mechanistic review of drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Camptothecin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fatty Liver; Hepatocytes; Humans; Irinotecan; Lipid Metabolism; Liver; Methotrexate; Mitochondria, Liver; Organoplatinum Compounds; Oxaliplatin; Perhexiline; Tamoxifen; Tetracycline; Valproic Acid | 2015 |
13 other study(ies) available for camptothecin and tamoxifen
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; HCT116 Cells; Humans; K562 Cells; MCF-7 Cells; Mice; Mice, Nude; Microtubules; Neoplasms; Polymerization; Sulfonamides; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Northern; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Female; Fluorouracil; Humans; Insulin-Like Growth Factor I; Laminin; Methotrexate; Microscopy, Electron; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1997 |
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Camptothecin; Cell Line; Glioblastoma; Humans; Irinotecan; Naphthalenes; Perylene; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2003 |
Effects of herbal supplements on the bioactivation of chemotherapeutic agents.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Cimicifuga; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hypericum; Inhibitory Concentration 50; Irinotecan; Microsomes, Liver; Plant Extracts; Regression Analysis; Tamoxifen; Tandem Mass Spectrometry; Zingiber officinale | 2013 |
In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism.
Topics: Camptothecin; Dose-Response Relationship, Drug; Herb-Drug Interactions; Humans; Irinotecan; Microsomes, Liver; Plant Preparations; Tamoxifen | 2014 |
Amphiphilic cyclodextrin nanoparticles for effective and safe delivery of anticancer drugs.
Topics: Antineoplastic Agents; Camptothecin; Cyclodextrins; Drug Delivery Systems; Humans; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Paclitaxel; Reproducibility of Results; Solubility; Tamoxifen | 2015 |
[Biomarkers for the prediction of adverse events].
Topics: Antineoplastic Agents; Biomarkers; Camptothecin; Fluorouracil; Humans; Irinotecan; Mercaptopurine; Tamoxifen | 2015 |
Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients.
Topics: Adult; Camptothecin; Carcinoma, Hepatocellular; Genistein; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Liver Neoplasms; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Propofol; Tamoxifen; Zidovudine | 2015 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |